Amlodipine reduces AngII-induced aortic aneurysms and atherosclerosis in hypercholesterolemic mice

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Chen, Xiaofeng ^a   Rateri, Debra L ^a   Howatt, Deborah A ^a   Balakrishnan, Anju ^a   Moorleghen, Jessica J ^a   Morris, Andrew J ^a   Charnigo, Richard ^b   Cassis, Lisa A ^b   Daugherty, Alan ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN II; LOW DENSITY LIPOPROTEIN RECEPTOR;

ANIMAL; AORTIC ANEURYSM; ATHEROSCLEROSIS; CHEMICALLY INDUCED; GENETICS; HYPERLIPOPROTEINEMIA TYPE II; KNOCKOUT MOUSE; MALE; METABOLISM; MOUSE;

AMLODIPINE; ANGIOTENSIN II; ANIMALS; AORTIC ANEURYSM; ATHEROSCLEROSIS; HYPERLIPOPROTEINEMIA TYPE II; MALE; MICE; MICE, KNOCKOUT; RECEPTORS, LDL;

EID: 84893521016     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0081743     Document Type: Article

References (72)

1. Bengtsson H, Sonesson B, Bergqvist D (1996) Incidence and prevalence of abdominal aortic aneurysms, estimated by necropsy studies and population screening by ultrasound. Ann NY Acad Sci 800: 1-24. doi:10.1111/j.1749-6632. 1996.tb33294.x. PubMed: 8958978. (Pubitemid 27028940)
2. Homme JL, Aubry MC, Edwards WD, Bagniewski SM, Shane Pankratz V et al. (2006) Surgical pathology of the ascending aorta: a clinicopathologic study of 513 cases. Am J Surg Pathol 30: 1159-1168. PubMed: 16931961. (Pubitemid 44299349)
3. Duncan JL, Harrild KA, Iversen L, Lee AJ, Godden DJ (2012) Long term outcomes in men screened for abdominal aortic aneurysm: prospective cohort study. BMJ 344: e2958. doi:10.1136/bmj.e2958. PubMed: 22563092.
4. Golledge J, Muller J, Daugherty A, Norman P (2006) Abdominal aortic aneurysm. Pathogenesis and implications for management. Arterioscler Thromb Vasc Biol 26: 2605-2613. doi:10.1161/01.ATV.0000245819.32762.cb. PubMed: 16973970.
5. Alcorn HG, Wolfson SK Jr, Sutton-Tyrrell K, Kuller LH, O'Leary D (1996) Risk factors for abdominal aortic aneurysms in older adults enrolled in The Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 16: 963-970. doi:10.1161/01.ATV.16.8.963. PubMed: 8696960. (Pubitemid 26266894)
6. Daugherty A, Lu H, Rateri DL, Cassis LA (2008) Augmentation of the renin-angiotensin system by hypercholesterolemia promotes vascular diseases. Future Lipidol 3: 625-636. doi:10.2217/17460875.3.6.625. PubMed: 19802341.
7. Rader DJ, Daugherty A (2008) Translating molecular discoveries into new therapies for atherosclerosis. Nature 451: 904-913. doi:10.1038/nature06796. PubMed: 18288179. (Pubitemid 351301745)
8. Daugherty A, Cassis L (1999) Chronic angiotensin II infusion promotes atherogenesis in low density lipoprotein receptor -/- mice. Ann NY Acad Sci 892: 108-118. doi:10.1111/j.1749-6632.1999.tb07789.x. PubMed: 10842656.
9. Daugherty A, Manning MW, Cassis LA (2000) Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest 105: 1605-1612. doi:10.1172/JCI7818. PubMed: 10841519. (Pubitemid 30390311)
10. Deng GG, Martin-McNulty B, Sukovich DA, Freay A, Halks-Miller M et al. (2003) Urokinase-type plasminogen activator plays a critical role in angiotensin II-induced abdominal aortic aneurysm. Circ Res 92: 510-517. doi:10.1161/01.RES.0000061571.49375.E1. PubMed: 12600880. (Pubitemid 36368663)
11. Uchida HA, Poduri A, Subramanian V, Cassis LA, Daugherty A (2011) Urokinase-type plasminogen activator deficiency in bone marrowderived cells augments rupture of angiotensin II-induced abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 31: 2845-2852. doi:10.1161/ATVBAHA.111.234997. PubMed: 21868698.
12. Daugherty A, Rateri DL, Charo IF, Owens AP, Howatt DA et al. (2010) Angiotensin II infusion promotes ascending aortic aneurysms: attenuation by CCR2 deficiency in apoE-/- mice. Clin Sci (Lond) 118: 681-689. doi:10.1042/ CS20090372.
13. Rateri DL, Moorleghen JJ, Knight V, Balakrishnan A, Howatt DA et al. (2012) Depletion of endothelial or smooth muscle cell-specific angiotensin II type 1a receptors does not influence aortic aneurysms or atherosclerosis in LDL receptor deficient mice. PLOS ONE 7: e51483. doi:10.1371/journal.pone.0051483. PubMed: 23236507.
14. Weiss D, Kools JJ, Taylor WR (2001) Angiotensin II-induced hypertension accelerates the development of atherosclerosis in apoEdeficient mice. Circulation 103: 448-454. doi:10.1161/01.CIR.103.3.448. PubMed: 11157699. (Pubitemid 32105987)
15. Manning MW, Cassis LA, Daugherty A (2003) Differential effects of doxycycline, a broad-spectrum matrix metalloproteinase inhibitor, on angiotensin II-induced atherosclerosis and abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 23: 483-488. doi:10.1161/01.ATV.0000058404.92759.32. PubMed: 12615694. (Pubitemid 36337226)
16. Suen RS, Rampersad SN, Stewart DJ, Courtman DW (2011) Differential Roles of Endothelin-1 in Angiotensin II-Induced Atherosclerosis and Aortic Aneurysms in Apolipoprotein E-Null Mice. Am J Pathol 179: 1549-1559. doi:10.1016/j.ajpath. 2011.05.014. PubMed: 21718678.
17. Subramanian V, Golledge J, Ijaz T, Bruemmer D, Daugherty A (2010) Pioglitazone-induced reductions in atherosclerosis occur via smooth muscle cell-specific interaction with PPAR{gamma}. Circ Res 107: 953-958. doi:10.1161/CIRCRESAHA.110.219089. PubMed: 20798360.
18. Henriques TA, Huang J, D'Souza SS, Daugherty A, Cassis LA (2004) Orchidectomy, but not ovariectomy, regulates angiotensin II-induced vascular diseases in apolipoprotein E-deficient mice. Endocrinology 145: 3866-3872. doi:10.1210/en.2003-1615. PubMed: 15105380. (Pubitemid 39037575)
19. King VL, Lin AY, Kristo F, Anderson TJ, Ahluwalia N et al. (2009) Interferon-gamma and the interferon-inducible chemokine CXCL10 protect against aneurysm formation and rupture. Circulation 119: 426-435. doi:10.1161/ CIRCULATIONAHA.108.785949. PubMed: 19139386.
20. Wang S, Subramanian V, Lu H, Howatt DA, Moorleghen JJ et al. (2012) Deficiency of receptor-associated protein attenuates angiotensin II-induced atherosclerosis in hypercholesterolemic mice without influencing abdominal aortic aneurysms. Atherosclerosis 220: 375-380. doi:10.1016/j.atherosclerosis. 2011.11.013. PubMed: 22153700.
21. Uchida HA, Kristo F, Rateri DL, Lu H, Charnigo R et al. (2010) Total lymphocyte deficiency attenuates AngII-induced atherosclerosis in males but not abdominal aortic aneurysms in apoE deficient mice. Atherosclerosis 211: 399-403. doi:10.1016/j.atherosclerosis.2010.02.034. PubMed: 20362292.
22. Rateri DL, Moorleghen JJ, Balakrishnan A, Owens AP 3rd, Howatt DA et al. (2011) Endothelial cell-specific deficiency of Ang II type 1a receptors attenuates Ang II-induced ascending aortic aneurysms in LDL receptor-/- mice. Circ Res 108: 574-581. doi:10.1161/CIRCRESAHA.110.222844. PubMed: 21252156.
23. Daugherty A, Manning MW, Cassis LA (2001) Antagonism of AT2 receptors augments angiotensin II-induced abdominal aortic aneurysms and atherosclerosis. Br J Pharmacol 134: 865-870. doi:10.1038/sj.bjp.0704331. PubMed: 11606327. (Pubitemid 33016158)
24. Cassis LA, Rateri DL, Lu H, Daugherty A (2007) Bone marrow transplantation reveals that recipient AT1a receptors are required to initiate angiotensin II-induced atherosclerosis and aneurysms. Arterioscler Thromb Vasc Biol 27: 380-386. PubMed: 17158350. (Pubitemid 46143055)
25. Wilmink AB, Vardulaki KA, Hubbard CS, Day NE, Ashton HA et al. (2002) Are antihypertensive drugs associated with abdominal aortic aneurysms? J Vasc Surg 36: 751-757. doi:10.1016/S0741-5214(02)00129-5. PubMed: 12368736. (Pubitemid 41122972)
26. Lichtlen PR, Hugenholtz PG, Raffenbeul W, Hecker H, Jost S et al. (1990) Retardation of angiographic progression of coronary artery disease by nifedipine: Results of International nifedipine Trial on Antiatherosclerotic therapy (INTACT). Lancet 1: 1109-1113. (Pubitemid 20159424)
27. Waters D, Lespérance J, Frncetish M, Causey D, Théroux P et al. (1990) A controlled clinical trial to assess the effect of a calcium channel blocker on the progression of coronary atherosclerosis. Circulation 82: 1940-1953. doi:10.1161/01.CIR.82.6.1940. PubMed: 2242520.
28. Zanchetti A, Bond MG, Hennig M, Neiss A, Mancia G et al. (2002) Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, longterm trial. Circulation 106: 2422-2427. doi:10.1161/01.CIR.0000039288.86470.DD. PubMed: 12417537. (Pubitemid 35278796)
29. Pitt B, Byington RP, Furberg CD, Hunninghake DB, Mancini GBJ et al. (2000) Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation 102: 1503-1510. doi:10.1161/01.CIR. 102.13.1503. PubMed: 11004140.
30. Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M et al. (2004) Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 292: 2217-2225. doi:10.1001/jama.292.18.2217. PubMed: 15536108.
31. Daugherty A, Rateri D, Lu H, Balakrishnan A (2009) Measuring blood pressure in mice using volume pressure recording, a tail-cuff method. J Vis Exp 1291: ([MedlinePgn:]) PubMed: 19488026.
32. Daugherty A, Rateri DL (1994) Presence of LDL receptor-related protein/alpha 2-macroglobulin receptors in macrophages of atherosclerotic lesions from cholesterol- fed New Zealand and heterozygous Watanabe heritable hyperlipidemic rabbits. Arterioscler Thromb 14: 2017-2024. doi:10.1161/01.ATV. 14.12.2017. PubMed: 7526898.
33. Bhatt J, Shah B, Kambli S, Subbaiah G, Singh S et al. (2007) Rapid and sensitive method for the determination of sibutramine active metabolites in human plasma by reversed-phase liquid chromatography-tandem mass spectroscopy. J Chromatogr Sci 45: 91-96. doi:10.1093/chromsci/45.2.91. PubMed: 17425138. (Pubitemid 46207397)
34. Cassis LA (1992) Downregulation of the renin-angiotensin system in streptozotocin-diabetic rats. Am J Physiol, 262: E105-E109. PubMed: 1733240.
35. Owens AP 3rd, Rateri DL, Howatt DA, Moore KJ, Tobias PS et al. (2011) MyD88 deficiency attenuates angiotensin II-induced abdominal aortic aneurysm formation independent of signaling through toll-like receptors 2 and 4. Arterioscler Thromb Vasc Biol 31: 2813-2819. doi:10.1161/ATVBAHA.111.238642. PubMed: 21960563.
36. Daugherty A, Whitman SC (2003) Quantification of atherosclerosis in mice. Methods Mol Biol 209: 293-309. PubMed: 12357958.
37. Daugherty A, Rateri DL (2005) Development of experimental designs for atherosclerosis studies in mice. Methods 36: 129-138. doi:10.1016/j.ymeth.2004. 11.008. PubMed: 15893934. (Pubitemid 40726145)
38. Lu H, Rateri DL, Daugherty A (2007) Immunostaining of mouse atherosclerosis lesions. Methods Mol Med 139: 77-94. doi:10.1007/978-1-59745- 571-8-4. PubMed: 18287665.
39. Findeisen HM, Gizard F, Zhao Y, Cohn D, Heywood EB et al. (2011) Telomerase deficiency in bone marrow-derived cells attenuates angiotensin II-induced abdominal aortic aneurysm formation. Arterioscler Thromb Vasc Biol 31: 253-260. doi:10.1161/ATVBAHA.110.218545. PubMed: 21088250.
40. Rateri DL, Howatt DA, Moorleghen JJ, Charnigo R, Cassis LA et al. (2011) Prolonged infusion of angiotensin II in apoE(-/-) mice promotes macrophage recruitment with continued expansion of abdominal aortic aneurysm. Am J Pathol 179: 1542-1548. doi:10.1016/j.ajpath.2011.05.049. PubMed: 21763672.
41. Yoshii T, Iwai M, Li Z, Chen R, Ide A et al. (2006) Regression of atherosclerosis by amlodipine via anti-inflammatory and anti-oxidative stress actions. Hypertens Res 29: 457-466. doi:10.1291/hypres.29.457. PubMed: 16940709. (Pubitemid 44109037)
42. Trion A, de Maat M, Jukema W, Maas A, Offerman E et al. (2006) Anti-atherosclerotic effect of amlodipine, alone and in combination with atorvastatin, in APOE*3-Leiden/hCRP transgenic mice. J Cardiovasc Pharmacol 47: 89-95. doi:10.1097/01.fjc.0000195603.65858.27. PubMed: 16424791. (Pubitemid 44378230)
43. Candido R, Allen TJ, Lassila M, Cao Z, Thallas V et al. (2004) Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosis. Circulation 109: 1536-1542. doi:10.1161/01.CIR.0000124061.78478.94. PubMed: 15023892. (Pubitemid 38420183)
44. Delsing DJM, Jukema JW, van de Wiel MA, Emeis JJ, van der Laarse A et al. (2003) Differential effects of amlodipine and atorvastatin treatment and their combination on atherosclerosis in ApoE*3-Leiden transgenic mice. J Cardiovasc Pharmacol 42: 63-70. doi:10.1097/00005344-200307000-00010. PubMed: 12827028. (Pubitemid 36791351)
45. Doran DE, Weiss D, Zhang Y, Griendling KK, Taylor WR (2007) Differential effects of AT(1) receptor and Ca(2+) channel blockade on atherosclerosis, inflammatory gene expression, and production of reactive oxygen species. Atherosclerosis 195: 39-47. doi:10.1016/j.atherosclerosis.2007.02.018. PubMed: 17224157. (Pubitemid 47561942)
46. Nussberger J, Aubert JF, Bouzourene K, Pellegrin M, Hayoz D et al. (2008) Renin inhibition by aliskiren prevents atherosclerosis progression: comparison with irbesartan, atenolol, and amlodipine. Hypertension 51: 1306-1311. doi:10.1161/HYPERTENSIONAHA.108.110932. PubMed: 18391092. (Pubitemid 351555942)
47. Das R, Burke T, Van Wagoner DR, Plow EF (2009) L-type calcium channel blockers exert an antiinflammatory effect by suppressing expression of plasminogen receptors on macrophages. Circ Res 105: 167-175. doi:10.1161/CIRCRESAHA.109.200311. PubMed: 19520970.
48. Jeppesen P, Bruun J, Nielsen-Kudsk F (1998) Amlodipine dynamic effects and myocardial pharmacokinetics in the isolated and perfused guinea-pig heart. Pharmacol Toxicol 82: 250-256. doi:10.1111/j.1600-0773.1998.tb01433.x. PubMed: 9646331. (Pubitemid 28270565)
49. Noguchi K, Takahashi K, Higuchi S (1998) In-vitro negative chronotropic and inotropic effects of a novel dihydropyridine derivative, CD-832, in the guinea-pig: comparison with calcium-channel antagonists. J Pharm Pharmacol 50: 329-334. doi:10.1111/j.2042-7158.1998.tb06869.x. PubMed: 9600727. (Pubitemid 28143604)
50. Faulkner JK, McGibney D, Chasseaud LF, Perry JL, Taylor IW (1986) The pharmacokinetics of amlodipine in healthy volunteers after single intravenous and after 14 repeated oral doses given once daily. Br J Clin Pharmacol 22: 21-25. doi:10.1111/j.1365-2125.1986.tb02874.x. PubMed: 2943308. (Pubitemid 17177199)
51. Bhatt J, Singh S, Subbaiah G, Shah B, Kambli S et al. (2007) A rapid and sensitive liquid chromatography-tandem mass spectrometry (LCMS/MS) method for the estimation of amlodipine in human plasma 21. Chromatogr: Biomed. pp. 169-175.
52. Cassis LA, Gupte M, Thayer S, Zhang X, Charnigo R et al. (2009) Angiotensin II infusion promotes abdominal aortic aneurysms independent of increased blood pressure in hypercholesterolemic mice. Am J Physiol Heart Circ Physiol 296: H1660-H1665. doi:10.1152/ajpheart.00028.2009. PubMed: 19252100.
53. Lu H, Cassis LA, Daugherty A (2007) Atherosclerosis and arterial blood pressure in mice. Curr Drug Targets 8: 1181-1189. doi:10.2174/ 138945007782403829. PubMed: 18045096. (Pubitemid 350238919)
54. Kanematsu Y, Kanematsu M, Kurihara C, Tsou TL, Nuki Y et al. (2010) Pharmacologically induced thoracic and abdominal aortic aneurysms in mice. Hypertension 55: 1267-1274. doi:10.1161/HYPERTENSIONAHA.109.140558. PubMed: 20212272.
55. Schricker K, Hamann M, Macher A, Krämer BK, Kaissling B et al. (1996) Effect of amlodipine on renin secretion and renin gene expression in rats. Br J Pharmacol 119: 744-750. doi:10.1111/j.1476-5381.1996.tb15735.x. PubMed: 8904650. (Pubitemid 26356588)
56. Lu H, Balakrishnan A, Howatt DA, Wu C, Charnigo R et al. (2012) Comparative effects of different modes of renin angiotensin system inhibition on hypercholesterolaemia-induced atherosclerosis. Br J Pharmacol 165: 2000-2008. doi:10.1111/j.1476-5381.2011.01712.x. PubMed: 22014125.
57. Lu H, Rateri DL, Feldman DL, Charnigo RJ Jr, Fukamizu A et al. (2008) Renin inhibition reduces hypercholesterolemia-induced atherosclerosis in mice. J Clin Invest 118: 984-993. PubMed: 18274671. (Pubitemid 351364606)
58. Daugherty A, Cassis LA, Lu H (2011) Complex pathologies of angiotensin II-induced abdominal aortic aneurysms. J Zhejiang Univ Sci B 12: 624-628. doi:10.1631/jzus.B1101002. PubMed: 21796801.
59. Bruemmer D, Daugherty A, Lu H, Rateri DL (2011) Relevance of angiotensin II-induced aortic pathologies in mice to human aortic aneurysms. Ann N Y Acad Sci 1245: 7-10. doi:10.1111/j.1749-6632.2011.06332.x. PubMed: 22211965.
60. Lu H, Rateri DL, Bruemmer D, Cassis LA, Daugherty A (2012) Involvement of the renin-angiotensin system in abdominal and thoracic aortic aneurysms. Clin Sci 123: 531-543. doi:10.1042/CS20120097. PubMed: 22788237.
61. Saraff K, Babamusta F, Cassis LA, Daugherty A (2003) Aortic dissection precedes formation of aneurysms and atherosclerosis in angiotensin II-infused, apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 23: 1621-1626. doi:10.1161/01.ATV.0000085631.76095.64. PubMed: 12855482. (Pubitemid 37108207)
62. Barisione C, Charnigo R, Howatt DA, Moorleghen JJ, Rateri DL et al. (2006) Rapid dilation of the abdominal aorta during infusion of angiotensin II detected by noninvasive high-frequency ultrasonography. J Vasc Surg 44: 372-376. doi:10.1016/j.jvs.2006.04.047. PubMed: 16890871. (Pubitemid 44142945)
63. Rossi-Foulkes R, Roman MJ, Rosen SE, Kramer-Fox R, Ehlers KH et al. (1999) Phenotypic features and impact of beta blocker or calcium antagonist therapy on aortic lumen size in the Marfan syndrome. Am J Cardiol 83: 1364-1368. doi:10.1016/S0002-9149(99)00101-0. PubMed: 10235096. (Pubitemid 29205747)
64. Yokokura H, Hiromatsu S, Akashi H, Kato S, Aoyagi S (2007) Effects of calcium channel blocker azelnidipine on experimental abdominal aortic aneurysms. Surg Today 37: 468-473. doi:10.1007/s00595-006-3367-6. PubMed: 17522763. (Pubitemid 46828749)
65. Tomita N, Yamasaki K, Izawa K, Kunugiza Y, Osako MK et al. (2008) Inhibition of experimental abdominal aortic aneurysm progression by nifedipine. Int J Mol Med 21: 239-244. PubMed: 18204791. (Pubitemid 351222858)
66. Mancini GB (2002) Antiatherosclerotic effects of calcium channel blockers. Prog Cardiovasc Dis 45: 1-20. doi:10.1016/S0033-0620(02)70007-8. PubMed: 12138411.
67. Weiss D, Taylor WR (2008) Deoxycorticosterone acetate salt hypertension in apolipoprotein E-/- mice results in accelerated atherosclerosis: the role of angiotensin II. Hypertension 51: 218-224. doi:10.1161/HYPERTENSIONAHA.107. 095885. PubMed: 18158357.
68. van de Poll SW, Delsing DJ, Jukema JW, Princen HM, Havekes LM et al. (2002) Raman spectroscopic investigation of atorvastatin, amlodipine, and both on atherosclerotic plaque development in APOE*3 Leiden transgenic mice. Atherosclerosis 164: 65-71. doi:10.1016/S0021-9150(02)00055-2. PubMed: 12119194. (Pubitemid 34765638)
69. van de Poll SW, Delsing DJ, Wouter Jukema J, Princen HM, Havekes LM et al. (2003) Effects of amlodipine, atorvastatin and combination of both on advanced atherosclerotic plaque in APOE*3-Leiden transgenic mice. J Mol Cell Cardiol 35: 109-118. doi:10.1016/S0022-2828(02)00284-5. PubMed: 12623305. (Pubitemid 36286973)
70. Nakandakare ER, Charf AM, Santos FC, Nunes VS, Ortega K et al. (2008) Dietary salt restriction increases plasma lipoprotein and inflammatory marker concentrations in hypertensive patients. Atherosclerosis 200: 410-416. doi:10.1016/j.atherosclerosis.2007.12.034. PubMed: 18262533.
71. Yue H, Uzui H, Shimizu H, Nakano A, Mitsuke Y et al. (2004) Different effects of calcium channel blockers on matrix metalloproteinase-2 expression in cultured rat cardiac fibroblasts. J Cardiovasc Pharmacol 44: 223-230. doi:10.1097/00005344-200408000-00012. PubMed: 15243304. (Pubitemid 38982166)
72. Kataoka C, Egashira K, Ishibashi M, Inoue S, Ni W et al. (2004) Novel anti-inflammatory actions of amlodipine in a rat model of arteriosclerosis induced by long-term inhibition of nitric oxide synthesis. Am J Physiol Heart Circ Physiol 286: H768-H774. doi:10.1152/ajpheart.00937.2002. PubMed: 14592942. (Pubitemid 38140360)